Drug Price Trends for TREMFYA

Average Pharmacy Cost for TREMFYA

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
TREMFYA 200 MG/2 ML PEN	57894-0651-01	7349.67030	ML	2026-02-03
TREMFYA 100 MG/ML ONE-PRESS	57894-0640-11	14766.32802	ML	2026-02-03
TREMFYA 100 MG/ML SYRINGE	57894-0640-01	14769.73527	ML	2026-02-03
TREMFYA 200 MG/2 ML PEN	57894-0651-02	7349.67030	ML	2026-02-03

Market Analysis and Price Projections for TREMFYA ( guselkumab)

Last updated: February 20, 2026

What is TREMFYA, and how is it positioned in the therapeutic landscape?

TREMFYA (guselkumab) is a monoclonal antibody targeting interleukin-23 (IL-23), approved by the FDA in July 2017 for moderate-to-severe plaque psoriasis. It is marketed by Janssen Pharmaceuticals. The drug has expanded indications to include active psoriatic arthritis (2018) and Crohn's disease (phase 3 trials).

The IL-23 inhibitor segment competes with other biologics such as Stelara (ustekinumab), Skyrizi (risankizumab), and Humira (adalimumab). Its differentiators include dosing frequency (every 8 weeks after initial doses) and clinical efficacy demonstrated in Phase 3 trials.

How large is the current market for IL-23 inhibitors?

In 2022, the global psoriasis market was valued at approximately $10.5 billion, with biologics accounting for 65%. IL-23 inhibitors, including TREMFYA, represent a rapidly growing segment, capturing roughly 35% of biologics sales for psoriasis, translating to around $2.4 billion.

Similarly, the psoriatic arthritis segment contributes another estimated $1.2 billion for IL-23 inhibitors. Overall, the IL-23 market across indications approaches $3.6 billion globally.

What are the key factors influencing TREMFYA’s market share?

• Efficacy and safety profile: Clinical trials show TREMFYA has superior skin clearance and lower adverse events relative to competitors.
• Dosing schedule: Q8W dosing after initial doses improves adherence, relative to other drugs requiring more frequent injections.
• Pricing strategy: Competitive pricing and reimbursement policies dictate patient access and sales volume.
• Market penetration: Early adoption by dermatologists and gastroenterologists affects growth; strategic marketing influences this.
• Regulatory approvals: Expanded indications boost sales potential, especially for psoriatic arthritis and Crohn’s disease.

What are current and projected sales figures?

Year	Estimated Global Sales (USD billion)	Notes
2022	900 million	Growth driven by psoriasis and psoriatic arthritis indications
2023	1.2 billion	Expansion into new markets, increased dosing adoption
2024	1.5 billion	Launches in additional countries, broadening of indications
2025	1.8 billion	Patent cliff approaching, new indications, increased competition

Note: These are estimates based on market reports and analyst forecasts.

How does pricing compare across IL-23 inhibitors?

Drug	Wholesale Acquisition Cost (WAC) per dose	Dosing Frequency	Approximate Annual Cost (USD)
TREMFYA	$5,500	Q8W after initial 2 doses	~$66,000
Skyrizi (risankizumab)	$6,000	Q12W	~$72,000
Stelara (ustekinumab)	$6,500	Q12W	~$78,000

Pricing remains competitive, with TREMFYA priced slightly below Skyrizi and Stelara, benefiting from its dosing schedule.

What are the main price drivers and challenges?

• Reimbursement policies: Payers favor drugs with proven efficacy and lower administration costs.
• Market exclusivity: Patent protections till 2029 help maintain pricing power.
• Biosimilar entry: Predicted biosimilar competition after patent expiry could exert downward pressure.
• Manufacturing costs: Monoclonal antibody production costs influence wholesale and retail prices.

What are the forecast risks and opportunities?

Risks:

• Emergence of biosimilars post-patent expiry.
• New competitors with improved efficacy or lower costs.
• Regulatory delays in new indications.

Opportunities:

• Increasing prevalence of psoriasis and psoriatic arthritis.
• Approval for Crohn’s disease and other autoimmune conditions.
• Patient adherence improvements through dosing convenience.

---

Key Takeaways

• TREMFYA’s market share benefits from its efficacy, dosing schedule, and competitive price point versus peers.
• The IL-23 inhibitor market is growing, with sales forecasted to reach approximately $1.8 billion globally by 2025.
• Pricing remains sensitive to biosimilar entry, reimbursement decisions, and competitive pressures.
• Expanding indications and geographic coverage are key to supporting continued sales growth.
• Patent expiry around 2029 will likely introduce biosimilar competition, pressing prices down.

---

FAQs

Q1: How does TREMFYA compare to Stelara in clinical efficacy?
A1: Clinical trials show TREMFYA offers higher skin clearance rates and fewer adverse events compared to Stelara, with a faster response time and better safety profile.

Q2: What impact will biosimilars have on TREMFYA’s pricing?
A2: Biosimilar competition post-2029 could reduce TreMFYA's price by 30-50%, depending on market uptake and regulatory policies.

Q3: Are there upcoming approvals that could boost TREMFYA’s sales?
A3: Yes, ongoing Phase 3 trials for Crohn’s disease may lead to a new indication, expanding the market potential.

Q4: How does TREMFYA’s dosing schedule affect market adoption?
A4: The Q8W maintenance dosing enhances patient adherence and reduces injection frequency, providing a competitive advantage over drugs requiring more frequent administration.

Q5: What are the prospects for TREMFYA in emerging markets?
A5: Market entry in Asia-Pacific, Latin America, and Africa is expected to accelerate sales, supported by local manufacturing agreements and pricing strategies.

---

References

1. MarketsandMarkets. (2022). Biologic Market for Autoimmune Diseases.
2. Evaluate Pharma. (2023). Global Biologics Market Data.
3. Janssen Pharmaceuticals. (2022). TREMFYA Prescribing Information.
4. IQVIA. (2023). Biologics Pricing Trends.
5. FDA. (2022). Approved and Pending IND Drugs for Autoimmune Conditions.